At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Brent Wood (University of Washington, Seattle, WA) discusses the phase III Children’s Oncology Group (COG) study AALL0434, which evaluated a standard 4-drug induction followed by response-based risk stratification, as determined by measured levels of minimal residual disease (MRD), in patients with T-lymphocytic leukemia. Intermediate and high-risk patients were randomized to receive or not receive additional nelarabine chemotherapy and all patients except those who were low-risk received additional radiation therapy.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates